Silence Therapeutics plc

Silence Therapeutics plc

SLNCF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.08B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Silence Therapeutics plcSilence Therapeutics plc-7.3--101%--
$0.31

Current Fair Value

95.2% downside

Overvalued by 95.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.08 Billion
Enterprise Value$1.01 Billion
Earnings per Share$-1.89
Beta1.41
Outstanding Shares165,600,827

Return

Return on Equity-101.36%ROE
Return on Assets-36.65%
Return on Invested Capital-80.87%

Valuation & Multiples

P/E Ratio-7.26P/E Ratio
PEG13.17PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1640.05
Enterprise Value to EBIT-13.31
Enterprise Value to Net Income-26
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$0.08
Est. -$0.07
Revenue Estimate
$1.70 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Silence Therapeutics Plc

74 employees
CEO: David Solomon

Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas ...

Questions & Answers